Amyloid light-chain amyloidosis
Clinical trials for Amyloid light-chain amyloidosis explained in plain language.
Never miss a new study
Get alerted when new Amyloid light-chain amyloidosis trials appear
Sign up with your email to follow new studies for Amyloid light-chain amyloidosis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare amyloidosis: targeted drug combo enters trial
Disease control Recruiting nowThis Phase 2 trial tests a new drug, belantamab mafodotin, combined with standard chemotherapy in 60 adults newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if the combination improves blood and organ responses. The stu…
Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to wipe out rare blood disease
Disease control Recruiting nowThis study tests whether two drugs, teclistamab and daratumumab, can safely and effectively treat AL amyloidosis, a rare disease where abnormal proteins damage organs. The treatment lasts about 6 months. Researchers will check if the drugs can make the abnormal proteins disappear…
Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Phase 2 • Sponsor: Rajshekhar Chakraborty, MD • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Mayo clinic launches gut bacteria study for rare plasma cell disorders
Knowledge-focused Recruiting nowThis study looks at the gut microbiome (the bacteria living in the digestive system) of people with POEMS syndrome, multiple myeloma, MGUS, AL amyloidosis, and healthy household members. Participants provide stool samples at home using a collection kit. The goal is to understand …
Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC